The molecular pathobiology of metastasis to the brain: A review

Neurosurgery Clinics of North America

Volumn 22, Issue 1, 2011, Pages 7-14

  Beasley, Kara D ^a,b,c   Toms, Steven A ^a,c  

^a GEISINGER MEDICAL CENTER   (United States)

^b PHILADELPHIA COLLEGE OF OSTEOPATHIC MEDICINE   (United States)

^c GEISINGER HEALTH SYSTEM   (United States)

Author keywords

Brain metastasis; Genetics; Molecular biology; Pathobiology

Indexed keywords

CATENIN; CD82 ANTIGEN; CHEMOKINE RECEPTOR CXCR4; CYCLOOXYGENASE 2; HEAT SHOCK PROTEIN 27; HERMES ANTIGEN; INTEGRIN; MATRIX METALLOPROTEINASE; METASTIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; T CELL FACTOR PROTEIN; TRANSFORMING GROWTH FACTOR BETA2; UVOMORULIN; VASCULOTROPIN; WNT PROTEIN;

BRAIN METASTASIS; CANCER CELL; CANCER STAGING; CELL ADHESION; CELL INTERACTION; DOWN REGULATION; ENZYME ACTIVITY; EXTRACELLULAR MATRIX; HUMAN; MACROPHAGE; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; TUMOR ESCAPE; UPREGULATION;

ANGIOGENIC PROTEINS; ANIMALS; BRAIN; BRAIN NEOPLASMS; HUMANS; NEOPLASM INVASIVENESS; NEOVASCULARIZATION, PATHOLOGIC;

EID: 78649418588     PISSN: 10423680     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nec.2010.08.009     Document Type: Review

References (67)

1. Horner MJ, Ries LAG, Krapcho M, et al, editors. SEER cancer statistics review, 1975-2006. Available at: Accessed March 25, 2010. http://seer.cancer.gov/csr/1975_2006/index.html.
2. Landis S.H., Murray T., Bolden S., et al. Cancer statistics, 1999. CA Cancer J Clin 1999, 49(1):8-31.
3. Patchell R.A. The management of brain metastases. Cancer Treat Rev 2003, 29(6):533-540.
4. Nathoo N., Chahlavi A., Barnett G.H., et al. Pathobiology of brain metastases. J Clin Pathol 2005, 58(3):237-242.
5. Bremnes R.M., Veve R., Hirsch F.R., et al. The E-cadherin cell-cell adhesion complex and lung cancer invasion, metastasis, and prognosis. Lung Cancer 2002, 36(2):115-124.
6. Shabani H.K., Kitange G., Tsunoda K., et al. Immunohistochemical expression of E-cadherin in metastatic brain tumors. Brain Tumor Pathol 2003, 20(1):7-12.
7. Yoshimasu T., Sakurai T., Oura S., et al. Increased expression of integrin alpha3beta1 in highly brain metastatic subclone of a human non-small cell lung cancer cell line. Cancer Sci 2004, 95(2):142-148.
8. Carbonell W.S., Ansorge O., Sibson N., et al. The vascular basement membrane as "soil" in brain metastasis. PLoS One 2009, 4(6):e5857.
9. Zheng Y., Lu Z. Paradoxical roles of FAK in tumor cell migration and metastasis. Cell Cycle 2009, 8(21):3474-3479.
10. Zheng Y., Xia Y., Hawke D., et al. FAK phosphorylation by ERK primes ras-induced tyrosine dephosphorylation of FAK mediated by PIN1 and PTP-PEST. Mol Cell 2009, 35(1):11-25.
11. Yamamoto M., Ueno Y., Hayashi S., et al. The role of proteolysis in tumor invasiveness in glioblastoma and metastatic brain tumors. Anticancer Res 2002, 22(6C):4265-4268.
12. Vassalli J.D., Sappino A.P., Belin D. The plasminogen activator/plasmin system. J Clin Invest 1991, 88(4):1067-1072.
13. Marchetti D., Denkins Y., Reiland J., et al. Brain-metastatic melanoma: a neurotrophic perspective. Pathol Oncol Res 2003, 9(3):147-158.
14. Denkins Y., Reiland J., Roy M., et al. Brain metastases in melanoma: roles of neurotrophins. Neuro-oncol 2004, 6(2):154-165.
15. Marchetti D., Nicolson G.L. Human heparanase: a molecular determinant of brain metastasis. Adv Enzyme Regul 2001, 41:343-359.
16. Bindal A.K., Hammoud M., Shi W.M., et al. Prognostic significance of proteolytic enzymes in human brain tumors. J Neurooncol 1994, 22(2):101-110.
17. Stamenkovic I. Extracellular matrix remodelling: the role of matrix metalloproteinases. J Pathol 2003, 200(4):448-464.
18. Jaalinoja J., Herva R., Korpela M., et al. Matrix metalloproteinase 2 (MMP-2) immunoreactive protein is associated with poor grade and survival in brain neoplasms. J Neurooncol 2000, 46(1):81-90.
19. Arnold S.M., Young A.B., Munn R.K., et al. Expression of p53, bcl-2, E-cadherin, matrix metalloproteinase-9, and tissue inhibitor of metalloproteinases-1 in paired primary tumors and brain metastasis. Clin Cancer Res 1999, 5(12):4028-4033.
20. Kruger A., Sanchez-Sweatman O.H., Martin D.C., et al. Host TIMP-1 overexpression confers resistance to experimental brain metastasis of a fibrosarcoma cell line. Oncogene 1998, 16(18):2419-2423.
21. Khaitan D., Sankpal U.T., Weksler B., et al. Role of KCNMA1 gene in breast cancer invasion and metastasis to brain. BMC Cancer 2009, 9:258.
22. Verkman A.S. Knock-out models reveal new aquaporin functions. Handb Exp Pharmacol 2009, 190:359-381.
23. Lee J.H., Welch D.R. Suppression of metastasis in human breast carcinoma MDA-MB-435 cells after transfection with the metastasis suppressor gene, KiSS-1. Cancer Res 1997, 57(12):2384-2387.
24. Shirasaki F., Takata M., Hatta N., et al. Loss of expression of the metastasis suppressor gene KiSS1 during melanoma progression and its association with LOH of chromosome 6q16.3-q23. Cancer Res 2001, 61(20):7422-7425.
25. Dong J.T., Suzuki H., Pin S.S., et al. Down-regulation of the KAI1 metastasis suppressor gene during the progression of human prostatic cancer infrequently involves gene mutation or allelic loss. Cancer Res 1996, 56(19):4387-4390.
26. Yang X., Welch D.R., Phillips K.K., et al. A putative marker for metastatic potential in human breast cancer. Cancer Lett 1997, 119(2):149-155.
27. Phillips K.K., White A.E., Hicks D.J., et al. Correlation between reduction of metastasis in the MDA-MB-435 model system and increased expression of the Kai-1 protein. Mol Carcinog 1998, 21(2):111-120.
28. Takaoka A., Hinoda Y., Sato S., et al. Reduced invasive and metastatic potentials of KAI1-transfected melanoma cells. Jpn J Cancer Res 1998, 89(4):397-404.
29. Shevde L.A., Welch D.R. Metastasis suppressor pathways-an evolving paradigm. Cancer Lett 2003, 198(1):1-20.
30. Odintsova E., Sugiura T., Berditchevski F. Attenuation of EGF receptor signaling by a metastasis suppressor, the tetraspanin CD82/KAI-1. Curr Biol 2000, 10(16):1009-1012.
31. Guan R.J., Ford H.L., Fu Y., et al. Drg-1 as a differentiation-related, putative metastatic suppressor gene in human colon cancer. Cancer Res 2000, 60(3):749-755.
32. Shah M.A., Kemeny N., Hummer A., et al. Drg1 expression in 131 colorectal liver metastases: correlation with clinical variables and patient outcomes. Clin Cancer Res 2005, 11(9):3296-3302.
33. Nam D.H., Jeon H.M., Kim S., et al. Activation of notch signaling in a xenograft model of brain metastasis. Clin Cancer Res 2008, 14(13):4059-4066.
34. Saito N., Hatori T., Murata N., et al. Comparison of metastatic brain tumour models using three different methods: the morphological role of the pia mater. Int J Exp Pathol 2008, 89(1):38-44.
35. Huysentruyt L.C., Mukherjee P., Banerjee D., et al. Metastatic cancer cells with macrophage properties: evidence from a new murine tumor model. Int J Cancer 2008, 123(1):73-84.
36. Bos P.D., Zhang X.H., Nadal C., et al. Genes that mediate breast cancer metastasis to the brain. Nature 2009, 459(7249):1005-1009.
37. Salmaggi A., Maderna E., Calatozzolo C., et al. CXCL12, CXCR4 and CXCR7 expression in brain metastases. Cancer Biol Ther 2009, 8(17):1608-1614.
38. Martin B., Aragues R., Sanz R., et al. Biological pathways contributing to organ-specific phenotype of brain metastatic cells. J Proteome Res 2008, 7(3):908-920.
39. Nguyen D.X., Chiang A.C., Zhang X.H., et al. WNT/TCF signaling through LEF1 and HOXB9 mediates lung adenocarcinoma metastasis. Cell 2009, 138(1):51-62.
40. Zhang C., Zhang F., Tsan R., et al. Transforming growth factor-beta2 is a molecular determinant for site-specific melanoma metastasis in the brain. Cancer Res 2009, 69(3):828-835.
41. Braun S., Pantel K., Muller P., et al. Cytokeratin-positive cells in the bone marrow and survival of patients with stage I, II, or III breast cancer. N Engl J Med 2000, 342(8):525-533.
42. Gao A.C., Lou W., Sleeman J.P., et al. Metastasis suppression by the standard CD44 isoform does not require the binding of prostate cancer cells to hyaluronate. Cancer Res 1998, 58(11):2350-2352.
43. Gao A.C., Lou W., Dong J.T., et al. CD44 is a metastasis suppressor gene for prostatic cancer located on human chromosome 11p13. Cancer Res 1997, 57(5):846-849.
44. Lou W., Krill D., Dhir R., et al. Methylation of the CD44 metastasis suppressor gene in human prostate cancer. Cancer Res 1999, 59(10):2329-2331.
45. Harabin-Slowinska M., Slowinski J., Konecki J., et al. Expression of adhesion molecule CD44 in metastatic brain tumors. Folia Neuropathol 1998, 36(3):179-184.
46. Li H., Liu J., Hofmann M., et al. Differential CD44 expression patterns in primary brain tumours and brain metastases. Br J Cancer 1995, 72(1):160-163.
47. Li J., Yen C., Liaw D., et al. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 1997, 275(5308):1943-1947.
48. Tamura M., Gu J., Matsumoto K., et al. Inhibition of cell migration, spreading, and focal adhesions by tumor suppressor PTEN. Science 1998, 280(5369):1614-1617.
49. Tamura M., Gu J., Takino T., et al. Tumor suppressor PTEN inhibition of cell invasion, migration, and growth: differential involvement of focal adhesion kinase and p130Cas. Cancer Res 1999, 59(2):442-449.
50. Hahn M., Wieland I., Koufaki O.N., et al. Genetic alterations of the tumor suppressor gene PTEN/MMAC1 in human brain metastases. Clin Cancer Res 1999, 5(9):2431-2437.
51. Chang C., Werb Z. The many faces of metalloproteases: cell growth, invasion, angiogenesis and metastasis. Trends Cell Biol 2001, 11(11):S37-S43.
52. Kim L.S., Huang S., Lu W., et al. Vascular endothelial growth factor expression promotes the growth of breast cancer brain metastases in nude mice. Clin Exp Metastasis 2004, 21(2):107-118.
53. Xia W., Unger P., Miller L., et al. The src-suppressed C kinase substrate, SSeCKS, is a potential metastasis inhibitor in prostate cancer. Cancer Res 2001, 61(14):5644-5651.
54. Bergers G., Brekken R., McMahon G., et al. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat Cell Biol 2000, 2(10):737-744.
55. Kono S., Rao J.S., Bruner J.M., et al. Immunohistochemical localization of plasminogen activator inhibitor type 1 in human brain tumors. J Neuropathol Exp Neurol 1994, 53(3):256-262.
56. Roodink I., Verrijp K., Raats J., et al. Plexin D1 is ubiquitously expressed on tumor vessels and tumor cells in solid malignancies. BMC Cancer 2009, 9:297.
57. Palmieri D., Fitzgerald D., Shreeve S.M., et al. Analyses of resected human brain metastases of breast cancer reveal the association between up-regulation of hexokinase 2 and poor prognosis. Mol Cancer Res 2009, 7(9):1438-1445.
58. Yaguchi H., Ohkura N., Tsukada T., et al. Menin, the multiple endocrine neoplasia type 1 gene product, exhibits GTP-hydrolyzing activity in the presence of the tumor metastasis suppressor nm23. J Biol Chem 2002, 277(41):38197-38204.
59. Ouatas T., Salerno M., Palmieri D., et al. Basic and translational advances in cancer metastasis: nm23. J Bioenerg Biomembr 2003, 35(1):73-79.
60. Sarris M., Scolyer R.A., Konopka M., et al. Cytoplasmic expression of nm23 predicts the potential for cerebral metastasis in patients with primary cutaneous melanoma. Melanoma Res 2004, 14(1):23-27.
61. Seraj M.J., Samant R.S., Verderame M.F., et al. Functional evidence for a novel human breast carcinoma metastasis suppressor, BRMS1, encoded at chromosome 11q13. Cancer Res 2000, 60(11):2764-2769.
62. Seraj M.J., Harding M.A., Gildea J.J., et al. The relationship of BRMS1 and RhoGDI2 gene expression to metastatic potential in lineage related human bladder cancer cell lines. Clin Exp Metastasis 2000, 18(6):519-525.
63. Liu Y., El-Naggar S., Darling D.S., et al. Zeb1 links epithelial-mesenchymal transition and cellular senescence. Development 2008, 135(3):579-588.
64. Wrage M., Ruosaari S., Eijk P.P., et al. Genomic profiles associated with early micrometastasis in lung cancer: relevance of 4q deletion. Clin Cancer Res 2009, 15(5):1566-1574.
65. Grinberg-Rashi H., Ofek E., Perelman M., et al. The expression of three genes in primary non-small cell lung cancer is associated with metastatic spread to the brain. Clin Cancer Res 2009, 15(5):1755-1761.
66. Narla G., DiFeo A., Fernandez Y., et al. KLF6-SV1 overexpression accelerates human and mouse prostate cancer progression and metastasis. J Clin Invest 2008, 118(8):2711-2721.
67. Micalizzi D.S., Christensen K.L., Jedlicka P., et al. The six1 homeoprotein induces human mammary carcinoma cells to undergo epithelial-mesenchymal transition and metastasis in mice through increasing TGF-beta signaling. J Clin Invest 2009, 119(9):2678-2690.